Smith & Nephew (SN.)
market vs.
industry GROWTH & VALUE
| 12m Forecast Rolling | ||||
| PE Ratio (f) | 14.7 |
|
|
|
| PEG Ratio (f) |
|
|
||
| EPS Growth (f) | % |
|
|
|
| Dividend Yield (f) | % |
|
|
|
| Valuation (ttm) | ||||
| Price to Book Value | 2.71 |
|
|
|
| Price to Tang. Book |
|
|
||
| Price to Free Cashflow |
|
|
||
| Price to Sales |
|
|
||
| EV to EBITDA |
|
|
||
market vs.
industry QUALITY
| Year End 31st Dec | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | TTM | 2013E | 2014E | CAGR / Avg | |
| Revenue | $m | ||||||||||
| Operating Profit | $m | ||||||||||
| Net Profit | $m | ||||||||||
| EPS Reported | $ | ||||||||||
| EPS Normalised | $ | ||||||||||
| EPS Growth | % | ||||||||||
| PE Ratio | x | ||||||||||
| PEG | x | ||||||||||
| Profitability | |||||||||||
| Operating Margin | % | ||||||||||
| ROA | % | ||||||||||
| ROCE | % | ||||||||||
| ROE | % | ||||||||||
| Cashflow | |||||||||||
| Op. Cashflow ps | $ | ||||||||||
| Capex ps | $ | ||||||||||
| Free Cashflow ps | $ | ||||||||||
| Last ex-div: 17th Apr, paid: 8th May more... Dividends | |||||||||||
| Dividend ps | $ | ||||||||||
| Dividend Growth | % | ||||||||||
| Dividend Yield | % | ||||||||||
| Dividend Cover | x | ||||||||||
| Balance Sheet | |||||||||||
| Cash etc | $m | ||||||||||
| Working Capital | $m | ||||||||||
| Net Fixed Assets | $m | ||||||||||
| Net Debt | $m | ||||||||||
| Book Value | $m | ||||||||||
| Average Shares | m | ||||||||||
| Book Value ps | $ | +16.2% | |||||||||
FINANCIAL BRIEF: For the three months ended 30 March 2013, Smith & Nephew plc revenues remained flat at $1.08B. Net income decreased 11% to $143M. Revenues reflect Advanced Wound Management segment increase of 31% to $315M, Emerging and International Markets segment increase of 15% to $130M, United States segment increase of 3% to $460M, also reflect Advance Surgical Devices segment decrease of 9% to $760M, Established Markets segment decrease of 7% to $485M. more »
| Leverage (ttm) | Total | Ex Intang | |||
| Gross Gearing | % | ||||
| Net Gearing | % | ||||
| Cash / Assets | % | ||||
| Liquidity (ttm) | ||
| Current Ratio | ||
| Quick Ratio | ||
| Interest Cover | ||
| Efficiency (ttm) | ||
| Asset Turnover | ||
| Rec's Turnover | ||
| Stock Turnover | ||
market vs.
industry RECENT HISTORY
| Latest interim period (ended 30th Mar '13) vs. prior year | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| 3yr Average Annualised | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| DPS Growth | % |
|
|
|
BROKER CONSENSUS & FORECAST TREND
| Recommendation: | Strong Sell | Sell | Hold | Buy | Strong Buy |
|---|---|---|---|---|---|
| No. of Analysts: | 0 | 3 | 13 | 3 | 2 |
Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (which includes arthroscopic procedures referred to as sports medicine) and advanced wound management. It operates in three segments: Orthopaedics, Endoscopy and Advanced Wound Management. It operates on a worldwide basis and has distribution channels in over 90 countries. Orthopaedic reconstruction implants include hip, knee and shoulder joints, as well as ancillary products, such as bone cement and mixing systems used in cemented reconstruction joint surgery. Endoscopy business develops and commercialises endoscopic (minimally invasive surgery) techniques, educational programmes and services. Advanced Wound Management business offers a range of products from initial wound bed preparation through to full wound closure. In May 2012, it acquired Kalypto Medical, Inc. In December 2012, the Company acquired the assets of Healthpoint Biotherapeutics.
Directors: Olivier Bohuon (CEO) 54, Julie Brown (CFO) 50, Michael Frazzette (Corp. Exec.) 50, Kelvin Johnson (Corp. Exec.) 61, Roger Teasdale (Corp. Exec.) 45, Francisco Vega (Corp. Exec.) 51, R. Gordon Howe (Sr. VP) 50, Ros Rivaz (CTO) 57, John Campo (Other) 58, Helen Maye (Other) 53,
No. of Employees: 10,500 No. of Shareholders: 19,122
| Last Annual | December 31st, 2012 |
| Last Interim | March 30th, 2013 |
| Shares in Issue | 907,040,075 |
| Free Float | 895.5m (98.7%) |
| Sector | Healthcare |
| Industry | Healthcare Equipment & Supplies |
| Index | FTSEUROFIRST 300 , E300 ex EURO COR, FTSE 350 Act , FTSE Lower Yield , FT350 Hlth Eq&sr , FTSE 100 , FTSE 100 Eod Gbp , FTSE Techmark Focus , FTSE Techmark All-share, |
| Exchange |
London Stock Exchange (Full) |
| Eligible for | an ISA? a SIPP? |
| Address | 15 Adam Street, LONDON, WC2N 6LA, United Kingdom |
| Web | http://www.smith-nephew.com |
| Phone | +44 20 74017646 |
| Contact | Kim Gunthorp (Investor Relations Manager) |
| Registrar | Equiniti Limited |
| Auditors | Ernst & Young LLP |
| Wed 5:54pm | Transaction in Own Shares |
| Tue 6:01pm | Transaction in Own Shares |
| Mon 5:57pm | Transaction in Own Shares |
| Mon 8:53am | Additional Listing |
| 17th May | Transaction in Own Shares |
| 15th May | Transaction in Own Shares |
Recent ↓
